No Data
No Data
Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement
①Tonight, lepu medical technology announced that General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned, and the Chairman's daughter Pu Fei took over as General Manager, with a "sea turtle elite" background; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, and the market cap has dropped by one quarter compared to its peak period.
lepu medical technology (300003.SZ): General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned for personal reasons.
On September 25th, lepu medical technology (300003.SZ) announced that the board of directors has recently received resignation reports from the company's general manager Mr. Zhang Zhibin and deputy general manager Mr. Zheng Guorui due to personal reasons, requesting to resign from their current positions in the company, and will no longer hold any position in the company after resignation. As of the date of this announcement, Mr. Zhang Zhibin holds 217,500 shares of the company, accounting for 0.0116% of the total share capital. Mr. Zheng Guorui holds 30,000 shares of the company, accounting for 0.0016% of the total share capital. They were nominated by the chairman of the board and passed the qualification review by the board's nomination committee.
Lepu Medical Technology (300003.SZ) plans to distribute 1.42 yuan per 10 shares, ex-dividend on September 20th.
Lepu Medical Technology (300003.SZ) announced that the company plans to distribute half-yearly equity to all shareholders in 2024: 1...
Lepu Medical Technology (300003.SZ): Terminates the implementation of the 2022 restricted stock incentive plan.
Lepu Medical Technology (300003.SZ) announced on September 9th that the performance assessment target at the company level for the first vesting period of the 2022 restricted stock incentive plan has been successfully achieved. However, due to the changes in internal and external environments faced by the company's operation, the performance assessment target for the second vesting period could not be met. Furthermore, considering the significant fluctuation of the company's current stock price compared to the grant price, it will be difficult to achieve the expected incentive purpose and effect by continuing the implementation of this incentive plan. Taking into account market environment factors, the actual operation situation of the company, long-term strategic planning, and the willingness of incentive recipients, after careful consideration, the board of directors has decided to terminate the implementation of the plan.
Did the aftermath of Lepu Medical Technology's (300003.SZ) "merger and acquisition for growth" strategy show up, with declining performance and high goodwill?
The development risks of "merger maniac" lepu medical technology seem to be emerging.
Lepu Medical Technology plans to reduce its shareholding by no more than 2% in Shengnuo Biotechnology (688117.SH).
On September 3, J.LUNGHUI: | Shenno Biology (688117.SH) Announced that the company recently received a notification letter from shareholder Lepu Medical Technology Regarding the shareholding plan, Lepu Medical Technology intends to reduce its total holdings in the company by no more than 2,240,000 shares, i.e. not more than 2% of the total share capital, due to the shareholder's own fund needs. The portion to be reduced through centralized bidding will be carried out within 3 months after 15 trading days from the date of this announcement, and the total number of shares to be reduced in any 90 consecutive natural days shall not exceed 1% of the total number of company shares.
No Data
No Data